The Lilly-sponsored study is the first to assess tirzepatide, the active ingredient in its blockbuster diabetes GLP-1 drug Mounjaro, in young children.
Sign up here.
Lilly said it has submitted the new data to global regulators to support expanded use of Mounjaro for children.
The drug helped patients significantly reduce their BMI, a measure of body fat based on height and weight that helps to define if a person is overweight or obese.
Lilly’s Mounjaro helps improve blood sugar control in children in late-stage trial
